Skip to main content
About the Institute
  • English
  • Français
  • Español

Breadcrumb

  1. Home
  2. Microbiota 3 - March 2018
  3. Improvement in insulin sensitivity after faecal microbiota transplant depends on the initial microbiota composition of recipients
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Microbiota 3 - March 2018
  3. Improvement in insulin sensitivity after faecal microbiota transplant depends on the initial microbiota composition of recipients
Gastroenterology

Improvement in insulin sensitivity after faecal microbiota transplant depends on the initial microbiota composition of recipients

Diabetes

Commented article - Adult section

By Pr. Harry Sokol
Gastroenterology and Nutrition, Saint-Antoine Hospital, Paris, France

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

About this article

Author

Image_DT FMT H Sokol Prof Harry Sokol
Created 26 August 2021
Updated 19 August 2024

Commentary on the original publication by Kootte et al. ( Cell Metab 2017)

The gut microbiota is involved in insulin resistance although there is limited evidence of a causal link. We compared the effect of faecal microbiota transplant (FMT) from a thin donor (allogeneic) to that of an auto-transplantation (autologous) in male patients with metabolic syndrome. While no metabolic change was observed 18 weeks after FMT, insulin sensitivity was significantly improved at six weeks in the allogeneic FMT group and this was associated with a change in microbiota composition. We also reported changes in plasma concentrations of metabolites, such as γ-aminobutyric acid, and showed that the metabolic response after FMT (defined as the improvement in insulin sensitivity six weeks after FMT) was present in patients with a microbial diversity reduced to basal level. In conclusion, the beneficial effects of FMT from thin donors on carbohydrate metabolism are associated with changes in gut microbiota and plasma metabolites, and can be predicted by the basal microbiota composition of the recipient.[4]

What is already known about the topic?

Obesity and related disorders, such as diabetes, require new therapeutic approaches because the current treatments, including lifestyle changes, and antidiabetic treatments are insufficiently effective in reducing morbidity and mortality. During the last decade, changes in gut microbiota composition have emerged as a potential new therapeutic strategy for improving insulin sensitivity [1]. Several studies have shown that gut microbiota composition is different between thin and obese animals, but also that the microbial composition may reflect impaired metabolic functions, in particular, with a disturbance of ingested food [2]. Finally, these animal studies have suggested a causal link between microbiota abnormalities and metabolic syndrome since the phenotype is transferable by FMT [2]. Although numerous observational studies have suggested correlations between an altered microbiota composition and metabolism in humans, the causality has been difficult to prove. The authors of this study have previously shown in a small pilot study that FMT from thin donors to men with metabolic syndrome induced an improvement in carbohydrate metabolism, together with changes in faecal and duodenal microbiota [3]. Based on these results, the authors have studied the short- and long-term effects of FMT from thin donors on gut microbiota composition in a larger group of men with metabolic syndrome and investigated the pathophysiology of insulin resistance by correlating changes in gut microbiota with several markers of metabolism. In addition, the authors have attempted to identify basal characteristics of the microbiota of recipients in order to explain the improvement in insulin sensitivity in some patients (referred to as metabolic responders) and not in others (non-responders).

Key points

  • FMT from thin donors improves insulin sensitivity in obese patients with metabolic syndrome

  • There is interindividual variability in the response and the latter is transient

  • The improvement in insulin sensitivity is related to changes in plasma metabolites

  • The response to FMT is dependent on initial microbiota composition in patients

What are the main results of this study?

Thirty-eight obese men with metabolic syndrome were included and randomized in the allogeneic (n = 26) or autologous (n = 12) FMT group. FMT was administered by nasoduodenal tube and repeated six weeks later. Eighteen weeks after FMT, no effect was observed on both the microbiota and the parameters of metabolic syndrome. However, six weeks after FMT, the microbiota of the allogeneic FMT group was changed and the metabolic parameters, in particular insulin sensitivity, were improved while no change was observed in the autologous FMT group (Figure 1). In contrast to their previous study, no change in faecal concentration of butyrate was observed [3]. However, allogeneic FMT was associated with an increase in faecal concentration of acetate, as well as changes in the blood level of about 30 metabolites, several of which are involved in the metabolism of tryptophan. In the subgroup of patients who favourably responded to allogeneic FMT, changes were observed in the faecal microbiota, such as, for example, an increase in Akkermansia muciniphila bacterium, and the favourable effects of this bacterium were demonstrated on metabolic syndrome in mice. The authors also highlighted that the basal microbiota composition, as well as a low diversity, were predictive of a good response to FMT.

Image

What are the practical consequences?

Interventions on the gut microbiota, and particularly FMT, are a valid therapeutic approach for metabolic syndrome. Nevertheless, there is high interindividual variability in the response, which may be related to factors from the host, but also from the donor. In addition, the effects are relatively modest with a single FMT and, at best, they are transient. More targeted strategies, such as the use of new generation probiotics (microbiota-derived bacteria) and prolonged administration, are therefore more attractive and are currently being studied.

Conclusion

This interventional study demonstrates that the gut microbiota plays a role in metabolic syndrome and is not just a passive stakeholder. The underlying mechanisms could involve the production of metabolites by the gut microbiota, which modulate the host signalling pathways. Nevertheless, the effects are relatively modest and transient. More targeted strategies, such as the use of new generation probiotics and prolonged administration, are therefore more attractive and are currently being studied.

Sources

1 Khan MT, Nieuwdorp M, Backhed F. Microbial modulation of insulin sensitivity. Cell Metab 2014 ; 20 : 753-60.

2 Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006 ; 444 : 1027-31.

3 Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012 ; 143 : 913-16.e7.

4 Kootte RS, Levin E, Salojärvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab 2017 ; 26 : 611-619.e6

 

Tags
Gastroenterology Insulin Microbiome Flora
    Focus
    Microbiota 3 - March 2018
    • Overview
      • Antibiotic treatment in infants: short and long-term consequences of the microbiome
    • Commented articles
      • Improvement in insulin sensitivity after faecal microbiota transplant depends on the initial microbiota composition of recipients
      • Stool contents of colicky infants induce visceral hypersensitivity in mice
    • Congress review
      • Report of the 30th congress of the european Helicobacter and microbiota study group
      • Focus on the Asian Pacific Digestive Disease Week
    • Press review
      • Intrapartum antibiotic prophylaxis for GBS infection
    Created 26 August 2021
    Updated 19 August 2024

    About this article

    To know more about this topic.

    Main topic

    Diabetes

    Content type

    Commented article

    Author

    Image_DT FMT H Sokol Prof Harry Sokol
    Antibiotic treatment in infants: short and long-term consequences of the microbiome
    Stool contents of colicky infants induce visceral hypersensitivity in mice
    Focus

    Microbiota 3 - March 2018

    Overview

    Antibiotic treatment in infants: short and long-term consequences of the microbiome

    Commented articles

    Improvement in insulin sensitivity after faecal microbiota transplant depends on the initial microbiota composition of recipients Stool contents of colicky infants induce visceral hypersensitivity in mice

    Congress review

    Report of the 30th congress of the european Helicobacter and microbiota study group Focus on the Asian Pacific Digestive Disease Week

    Press review

    Intrapartum antibiotic prophylaxis for GBS infection
    Gastroenterology
    Actu PRO : Malnutrition : agir sur le microbiote pour améliorer la croissance, un prototype à l’essai
    08.07.2021

    Malnutrition: acting on the microbiota in order to improve growth, a trial prototype

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article
    Actu PRO : Alcoolisme : expliquer les troubles sociaux grâce au microbiote
    27.01.2021

    Alcoholism: explaining social disorders thanks to the microbiota

    Read the article

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial...

    Find out more
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo